Company · CIK 0001384101 · SIC 8071 — Services-Medical Laboratories · Nasdaq
VERACYTE, INC. · VCYT
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 21, 2026 SForm 4 → | Sep 22, 5:16 pm EDT | John LeiteGlobal Chief Commercial Off | 4,015 | $40.00 | $160,600 | 124,329 | −3.13% | 10b5-1 |
| Sep 14, 2026 SForm 4 → | Sep 16, 4:08 pm EDT | Jens HolsteinDirector | 5,000 | $40.95 | $204,747 | 27,471 | −15.4% | 10b5-1 |
| Sep 4, 2026 SForm 4 → | Sep 4, 7:54 pm EDT | Phillip G. FebboChief Scientific & Med Officer | 13,110 | $43.05 | $564,410 | 133,048 | −8.97% | 10b5-1 |
| Sep 4, 2026 SForm 4 → | Sep 4, 7:54 pm EDT | Rebecca ChambersChief Financial Officer | 3,652 | $43.10 | $157,394 | 166,025 | −2.15% | 10b5-1 |
| Sep 4, 2026 SForm 4 → | Sep 4, 7:54 pm EDT | Annie McGuireEVP, General Counsel | 3,254 | $43.09 | $140,212 | 131,160 | −2.42% | 10b5-1 |
| Sep 2, 2026 FForm 4 → | Sep 4, 7:54 pm EDT | Jonathan WygantVP, Chief Accounting Officer | 1,361 | $44.88 | $61,082 | 43,226 | — | |
| Sep 2, 2026 FForm 4 → | Sep 4, 7:54 pm EDT | John LeiteGlobal Chief Commercial Off | 3,961 | $44.88 | $177,770 | 128,344 | — | |
| Sep 2, 2026 FForm 4 → | Sep 4, 7:54 pm EDT | Phillip G. FebboChief Scientific & Med Officer | 3,639 | $44.88 | $163,318 | 146,158 | — | 10b5-1 |
| Sep 2, 2026 FForm 4 → | Sep 4, 7:54 pm EDT | Rebecca ChambersChief Financial Officer | 3,603 | $44.88 | $161,703 | 169,677 | — | 10b5-1 |
| Sep 2, 2026 FForm 4 → | Sep 4, 7:54 pm EDT | Annie McGuireEVP, General Counsel | 3,215 | $44.88 | $144,289 | 134,414 | — | 10b5-1 |
| Sep 2, 2026 FForm 4 → | Sep 4, 7:53 pm EDT | Marc StapleyChief Executive Officer, Director | 8,782 | $44.88 | $394,136 | 432,073 | — | |
| Sep 1, 2026 SForm 4 → | Sep 3, 4:48 pm EDT | Muna BhanjiDirector | 1,864 | $42.97 | $80,096 | 42,718 | −4.18% | 10b5-1 |
Reported at this company — derivatives (options, RSUs, warrants)
No reported derivative activity in this period.